StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) stock

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302571% above fair value
$413.26+1.97 (+0.48%)

Close on Nov 17, 2026Market cap $46.99BP/E 73.9Yield –

BeOne Medicines operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

BeOne Medicines's operating cash flow for the twelve months ending Jun 30, 2026 was $1.48B, up 159.8% year over year. For fiscal 2025 it was $1.13B. The highest annual figure on record is $1.13B in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.13B–
FY2024Dec 31, 2024-$140.63M–
FY2023Dec 31, 2023-$1.16B–
FY2022Dec 31, 2022-$1.50B–
FY2021Dec 31, 2021-$1.30B–
FY2020Dec 31, 2020-$1.28B–
FY2019Dec 31, 2019-$750.27M–
FY2018Dec 31, 2018-$547.72M-4395.1%
FY2017Dec 31, 2017$12.75M–
FY2016Dec 31, 2016-$89.51M–
FY2015Dec 31, 2015-$39.84M–
FY2014Dec 31, 2014-$8.69M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$462.82M+75.6%
Q1 FY2026Mar 31, 2026$201.34M+356.7%
Q4 FY2025Dec 31, 2025$417.35M+455.3%
Q3 FY2025Sep 30, 2025$402.55M+113.7%
Q2 FY2025Jun 30, 2025$263.60M–
Q1 FY2025Mar 31, 2025$44.08M–
Q4 FY2024Dec 31, 2024$75.16M–
Q3 FY2024Sep 30, 2024$188.37M–
Q2 FY2024Jun 30, 2024-$95.59M–
Q1 FY2024Mar 31, 2024-$308.57M–
Q4 FY2023Dec 31, 2023-$221.64M–
Q3 FY2023Sep 30, 2023-$78.15M–
Q2 FY2023Jun 30, 2023-$293.89M–
Q1 FY2023Mar 31, 2023-$563.78M–
Q4 FY2022Dec 31, 2022-$318.19M–
Q3 FY2022Sep 30, 2022-$561.91M–
Q2 FY2022Jun 30, 2022-$379.96M–
Q1 FY2022Mar 31, 2022-$236.56M-289.1%
Q4 FY2021Dec 31, 2021-$507.84M–
Q3 FY2021Sep 30, 2021-$495.71M–
Q2 FY2021Jun 30, 2021-$420.27M–
Q1 FY2021Mar 31, 2021$125.10M–
Q4 FY2020Dec 31, 2020-$332.33M–
Q3 FY2020Sep 30, 2020-$346.24M–
Q2 FY2020Jun 30, 2020-$262.94M–
Q1 FY2020Mar 31, 2020-$341.94M–
Q4 FY2019Dec 31, 2019-$267.18M–
Q3 FY2019Sep 30, 2019-$265.01M–
Q2 FY2019Jun 30, 2019-$46.10M–
Q1 FY2019Mar 31, 2019-$171.98M–
Q4 FY2018Dec 31, 2018-$193.89M-306.8%
Q3 FY2018Sep 30, 2018-$132.19M-2102.8%
Q2 FY2018Jun 30, 2018-$117.14M–
Q1 FY2018Mar 31, 2018-$104.50M–
Q4 FY2017Dec 31, 2017$93.75M–
Q3 FY2017Sep 30, 2017$6.60M–
Q2 FY2017Jun 30, 2017-$51.89M–
Q1 FY2017Mar 31, 2017-$35.71M–
Q4 FY2016Dec 31, 2016-$26.14M–
Q3 FY2016Sep 30, 2016-$24.28M–

More BeOne Medicines figures

See a number that looks wrong?